Physician profile
John Thomas Halgren
NPI 1700835055
$1,677.18
in general payments reported to CMS, 2019-2025
19 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $17.18 · 2021: $33.52 · 2022: $165 · 2023: $446 · 2024: $368 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $584.50 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $265.20 | 2022-2025 | |
| Alcon Vision LLC | $151.60 | 2019 | |
| Biotissue Holdings INC. | $117.27 | 2022-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $112.19 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $56.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $56.50 | 2022-2023 | |
| Allergan, INC. | $52.74 | 2019-2022 | |
| Glaukos Corporation | $49.43 | 2024 | Idose |
| Coherus Oncology, INC. | $45.86 | 2023-2024 | |
| Tarsus Pharmaceuticals, INC. | $35.83 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $30.77 | 2019-2023 | Tepezza |
| Rxsight INC | $20.50 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $19.57 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $19.06 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $16.81 | 2024 | |
| Sun Pharmaceutical Industries INC. | $16.61 | 2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $14.46 | 2021 | |
| Shire North American Group INC | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Halgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.